Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Propel Bio Management, LLC
Form 13F · Q2 2026

Propel Bio Management, LLC

CIK 1969764Filed 2026-08-1313F-HR View the filing on EDGAR ↗
$191M
Reported book value
29
Positions
11
Quarters on record
Top 50
Positions

Propel Bio Management, LLC — holdings

Top 29 positions of 29, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1PAGP Plains Gp Hldgs L P1.3M+0.0%$31M16.2%
2QUIT Achieve Life Science Inc4.0M+6.5%$26M13.8%
3CORT Corcept Therapeutics Inc136,499−7.7%$12M6.2%
4PHAT Phathom Pharmaceuticals Inc1.1M+24.9%$11M6.0%
5DCTH Delcath Sys Inc871,460−11.0%$11M5.7%
6MIST Milestone Pharmaceuticals In7.4M+80.4%$10M5.2%
7CMPS Compass Pathways Plc573,086−22.8%$8M4.2%
8KYTX Kyverna Therapeutics Inc883,198+37.1%$8M4.1%
9ARTV Artiva Biotherapeutics Inc696,436+375.8%$7M3.5%
10ABEO Abeona Therapeutics Inc983,070−26.1%$6M3.2%
11AQST Aquestive Therapeutics Inc1.4M+102.9%$6M3.1%
12PALI Palisade Bio Inc2.6M+131.6%$5M2.8%
13IMUX Immunic Inc325,022—$5M2.6%
14IVA Inventiva Sa1.3M+76.8%$5M2.5%
15SABS Sab Biotherapeutics Inc1.1M+6.3%$4M2.2%
16OBIO Orchestra Biomed Hldgs Inc896,701+0.0%$4M2.0%
17CLDX Celldex Therapeutics Inc New103,695−21.1%$4M2.0%
18ZVRA Zevra Therapeutics Inc253,544−10.2%$4M1.9%
19OCUL Ocular Therapeutix Inc357,966−6.4%$4M1.8%
20FDMT 4D Molecular Therapeutics In252,654−33.6%$3M1.8%
21OVID Ovid Therapeutics Inc1.1M+21.1%$3M1.6%
22EYPT Eyepoint Inc191,745−11.2%$3M1.4%
23UPB Upstream Bio Inc350,389+2.5%$2M1.3%
24SCYX Scynexis Inc543,478—$2M1.2%
25SLN Silence Therapeutics Plc191,733—$2M1.1%
26LONA Leonabio Inc149,279+0.0%$1M0.7%
27MAZE Maze Therapeutics Inc43,798+0.0%$1M0.7%
28CRVS Corvus Pharmaceuticals Inc70,380−18.0%$1M0.6%
29SGMT Sagimet Biosciences Inc125,878—$973,0370.5%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.